However, several limitations or further works should be considered: (1) The biological activities of bFGF are mediated by FGF receptors, so changes in bFGF and its receptors need to be further analyzed in the kidney; (2) A multi-analytical platform is recommended to detect more detailed metabolic pathway changes; (3) A multi-omics analysis will advance a better understanding of the therapeutic effect of bFGF on diabetic nephropathy and its potential mechanisms. The gene discussed is FGF2; the disease is diabetic kidney disease.